尽管分析师平均"持有"评价, 生物的Q1结果导致HC Wainwright的买入评级. Biogen's mixed Q1 results lead to a Buy rating from HC Wainwright, despite an average "Hold" from analysts.

HC Wainwright重申Biogen(BIIB)的买入评级, 目标价格为187美元, HC Wainwright reaffirmed a Buy rating on Biogen (BIIB) with a $187 target price, amidst mixed analyst opinions. 生物基因的Q1结果显示,收入为24.3亿美元,但未能达到EPS的预期值3.02美元。 Biogen's Q1 results showed a revenue beat at $2.43 billion but missed EPS expectations at $3.02. 分析家预测该年度的EPS为15.83。 Analysts predict a 15.83 EPS for the year. 股价平均为188.48美元,平均目标价为184.7亿美元,市场上限为184.7亿美元,PE比率为12.45,贝塔比率为0.14。 The stock has a "Hold" average rating, $188.48 average target price, market cap of $18.47 billion, PE ratio of 12.45, and a beta of 0.14.